Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Perflutren,Immunoglobulin G 285-292
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia
Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.
Brand Name : Albutein
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 27, 2020
Lead Product(s) : Perflutren,Immunoglobulin G 285-292
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?